|
1
|
Dengue: an escalating problem.
|
BMJ
|
2002
|
6.09
|
|
2
|
Safety and efficacy of a recombinant hepatitis E vaccine.
|
N Engl J Med
|
2007
|
5.87
|
|
3
|
Serotype-specific dengue virus circulation and dengue disease in Bangkok, Thailand from 1973 to 1999.
|
Am J Trop Med Hyg
|
2003
|
4.75
|
|
4
|
High circulating levels of the dengue virus nonstructural protein NS1 early in dengue illness correlate with the development of dengue hemorrhagic fever.
|
J Infect Dis
|
2002
|
4.69
|
|
5
|
Differing influences of virus burden and immune activation on disease severity in secondary dengue-3 virus infections.
|
J Infect Dis
|
2002
|
4.67
|
|
6
|
Epidemiology of inapparent and symptomatic acute dengue virus infection: a prospective study of primary school children in Kamphaeng Phet, Thailand.
|
Am J Epidemiol
|
2002
|
4.62
|
|
7
|
Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand.
|
J Infect Dis
|
2004
|
3.68
|
|
8
|
Burden of symptomatic dengue infection in children at primary school in Thailand: a prospective study.
|
Lancet
|
2007
|
3.52
|
|
9
|
Dengue Virus (DV) enhancing antibody activity in preillness plasma does not predict subsequent disease severity or viremia in secondary DV infection.
|
J Infect Dis
|
2005
|
2.78
|
|
10
|
Spatial and temporal circulation of dengue virus serotypes: a prospective study of primary school children in Kamphaeng Phet, Thailand.
|
Am J Epidemiol
|
2002
|
2.34
|
|
11
|
The comparative accuracy of 8 commercial rapid immunochromatographic assays for the diagnosis of acute dengue virus infection.
|
Clin Infect Dis
|
2006
|
2.33
|
|
12
|
Analysis of repeat hospital admissions for dengue to estimate the frequency of third or fourth dengue infections resulting in admissions and dengue hemorrhagic fever, and serotype sequences.
|
Am J Trop Med Hyg
|
2007
|
2.06
|
|
13
|
Dengue hemorrhagic fever in infants: research opportunities ignored.
|
Emerg Infect Dis
|
2002
|
2.03
|
|
14
|
Dengue plaque reduction neutralization test (PRNT) in primary and secondary dengue virus infections: How alterations in assay conditions impact performance.
|
Am J Trop Med Hyg
|
2009
|
1.93
|
|
15
|
Dengue hemorrhagic fever: the sensitivity and specificity of the world health organization definition for identification of severe cases of dengue in Thailand, 1994-2005.
|
Clin Infect Dis
|
2010
|
1.89
|
|
16
|
Experimental dengue virus challenge of human subjects previously vaccinated with live attenuated tetravalent dengue vaccines.
|
J Infect Dis
|
2012
|
1.87
|
|
17
|
Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine.
|
Am J Trop Med Hyg
|
2003
|
1.65
|
|
18
|
West Nile virus/dengue type 4 virus chimeras that are reduced in neurovirulence and peripheral virulence without loss of immunogenicity or protective efficacy.
|
Proc Natl Acad Sci U S A
|
2002
|
1.65
|
|
19
|
T cell responses to an HLA-B*07-restricted epitope on the dengue NS3 protein correlate with disease severity.
|
J Immunol
|
2002
|
1.62
|
|
20
|
Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naïve adults.
|
Hum Vaccin
|
2009
|
1.61
|
|
21
|
Prospective study to determine accuracy of rapid serological assays for diagnosis of acute dengue virus infection in Laos.
|
Clin Vaccine Immunol
|
2007
|
1.54
|
|
22
|
Transplacentally transferred maternal-infant antibodies to dengue virus.
|
Am J Trop Med Hyg
|
2003
|
1.48
|
|
23
|
Dengue epidemiology: virus epidemiology, ecology, and emergence.
|
Adv Virus Res
|
2003
|
1.45
|
|
24
|
Large epidemic of adenovirus type 4 infection among military trainees: epidemiological, clinical, and laboratory studies.
|
Clin Infect Dis
|
2002
|
1.45
|
|
25
|
Seizures and raised intracranial pressure in Vietnamese patients with Japanese encephalitis.
|
Brain
|
2002
|
1.44
|
|
26
|
Structure and age of genetic diversity of dengue virus type 2 in Thailand.
|
J Gen Virol
|
2006
|
1.43
|
|
27
|
Cytokine gene expression and protein production in peripheral blood mononuclear cells of children with acute dengue virus infections.
|
J Med Virol
|
2002
|
1.37
|
|
28
|
An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model.
|
Vaccine
|
2005
|
1.30
|
|
29
|
Development and evaluation of AS03, an Adjuvant System containing α-tocopherol and squalene in an oil-in-water emulsion.
|
Expert Rev Vaccines
|
2012
|
1.28
|
|
30
|
Clinical and immunological risk factors for severe disease in Japanese encephalitis.
|
Trans R Soc Trop Med Hyg
|
2002
|
1.27
|
|
31
|
Dengue-specific T cell responses in peripheral blood mononuclear cells obtained prior to secondary dengue virus infections in Thai schoolchildren.
|
J Infect Dis
|
2002
|
1.26
|
|
32
|
Clinical and epidemiological relevance of quantitating hepatitis E virus-specific immunoglobulin M.
|
Clin Diagn Lab Immunol
|
2002
|
1.23
|
|
33
|
Retracted
Evidence that rodents are a reservoir of hepatitis E virus for humans in Nepal.
|
J Clin Microbiol
|
2002
|
1.20
|
|
34
|
Interferon alfa-2a in Japanese encephalitis: a randomised double-blind placebo-controlled trial.
|
Lancet
|
2003
|
1.19
|
|
35
|
Quantitation of immunoglobulin to hepatitis E virus by enzyme immunoassay.
|
Clin Diagn Lab Immunol
|
2002
|
1.17
|
|
36
|
Antibody levels to hepatitis E virus in North Carolina swine workers, non-swine workers, swine, and murids.
|
Am J Trop Med Hyg
|
2002
|
1.16
|
|
37
|
A comparative study of leptospirosis and dengue in Thai children.
|
PLoS Negl Trop Dis
|
2007
|
1.15
|
|
38
|
Cellular immune activation in children with acute dengue virus infections is modulated by apoptosis.
|
J Infect Dis
|
2006
|
1.12
|
|
39
|
Protection of Rhesus monkeys against dengue virus challenge after tetravalent live attenuated dengue virus vaccination.
|
J Infect Dis
|
2006
|
1.08
|
|
40
|
Hospital-based diagnosis of hemorrhagic fever, encephalitis, and hepatitis in Cambodian children.
|
Emerg Infect Dis
|
2002
|
1.08
|
|
41
|
Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus-naive infants.
|
Am J Trop Med Hyg
|
2011
|
1.06
|
|
42
|
TNF and LTA gene, allele, and extended HLA haplotype associations with severe dengue virus infection in ethnic Thais.
|
J Infect Dis
|
2009
|
1.06
|
|
43
|
Modification of dengue virus strains by passage in primary dog kidney cells: preparation of candidate vaccines and immunization of monkeys.
|
Am J Trop Med Hyg
|
2003
|
1.05
|
|
44
|
Characterization of antibody responses to combinations of a dengue virus type 2 DNA vaccine and two dengue virus type 2 protein vaccines in rhesus macaques.
|
J Virol
|
2006
|
1.04
|
|
45
|
Role of U.S. military research programs in the development of U.S.-licensed vaccines for naturally occurring infectious diseases.
|
Vaccine
|
2007
|
1.04
|
|
46
|
Scientific consultation on immunological correlates of protection induced by dengue vaccines report from a meeting held at the World Health Organization 17-18 November 2005.
|
Vaccine
|
2007
|
1.03
|
|
47
|
Rapid type-specific diagnosis of adenovirus type 4 infection using a hexon-based quantitative fluorogenic PCR.
|
Diagn Microbiol Infect Dis
|
2002
|
1.02
|
|
48
|
Extended antigen sparing potential of AS03-adjuvanted pandemic H1N1 vaccines in children, and immunological equivalence of two formulations of AS03-adjuvanted H1N1 vaccines: results from two randomised trials.
|
BMC Infect Dis
|
2013
|
0.95
|
|
49
|
Hepatitis E antibody kinetics in Nepalese patients.
|
Trans R Soc Trop Med Hyg
|
2006
|
0.95
|
|
50
|
Role of US military research programs in the development of US Food and Drug Administration--approved antimalarial drugs.
|
Clin Infect Dis
|
2006
|
0.93
|
|
51
|
Characterization of dengue-2 virus binding to surfaces of mammalian and insect cells.
|
Am J Trop Med Hyg
|
2005
|
0.93
|
|
52
|
Vaccination of rhesus macaques against dengue-2 virus with a plasmid DNA vaccine encoding the viral pre-membrane and envelope genes.
|
Am J Trop Med Hyg
|
2003
|
0.92
|
|
53
|
Immunological priming induced by a two-dose series of H5N1 influenza antigen, administered alone or in combination with two different formulations of AS03 adjuvant in adults: results of a randomised single heterologous booster dose study at 15 months.
|
Vaccine
|
2011
|
0.91
|
|
54
|
US Military contributions to the global response to pandemic chikungunya.
|
Vaccine
|
2012
|
0.90
|
|
55
|
Comparative analysis reveals no consistent association between the secondary structure of the 3'-untranslated region of dengue viruses and disease syndrome.
|
J Gen Virol
|
2006
|
0.88
|
|
56
|
Evidence that rodents are a reservoir of hepatitis E virus for humans in Nepal.
|
J Clin Microbiol
|
2006
|
0.88
|
|
57
|
Randomized, multicenter trial of a single dose of AS03-adjuvanted or unadjuvanted H1N1 2009 pandemic influenza vaccine in children 6 months to <9 years of age: safety and immunogenicity.
|
Pediatr Infect Dis J
|
2012
|
0.86
|
|
58
|
Evaluation of a rapid quantitative diagnostic test for adenovirus type 4.
|
Clin Infect Dis
|
2004
|
0.86
|
|
59
|
Long-term immunogenicity of an AS03-adjuvanted influenza A(H1N1)pdm09 vaccine in young and elderly adults: an observer-blind, randomized trial.
|
Vaccine
|
2013
|
0.85
|
|
60
|
A Phase 2 study of a purified, inactivated virus vaccine to prevent Japanese encephalitis.
|
Vaccine
|
2007
|
0.84
|
|
61
|
The study transplacental chikungunya virus antibody kinetics, Thailand.
|
Emerg Infect Dis
|
2006
|
0.84
|
|
62
|
Safety and persistence of immunological response 6 months after intramuscular vaccination with an AS03-adjuvanted H1N1 2009 influenza vaccine: an open-label, randomized trial in Japanese children aged 6 months to 17 years.
|
Hum Vaccin Immunother
|
2012
|
0.84
|
|
63
|
Infectious diseases investment decision evaluation algorithm: a quantitative algorithm for prioritization of naturally occurring infectious disease threats to the U.S. military.
|
Mil Med
|
2008
|
0.82
|
|
64
|
Development and evaluation of an efficient 3'-noncoding region based SARS coronavirus (SARS-CoV) RT-PCR assay for detection of SARS-CoV infections.
|
J Virol Methods
|
2004
|
0.82
|
|
65
|
A model international partnership for community-based research on vaccine-preventable diseases: the Kamphaeng Phet-AFRIMS Virology Research Unit (KAVRU).
|
Vaccine
|
2013
|
0.78
|
|
66
|
Characterization of monoclonal antibodies to hepatitis E virus (HEV) capsid protein and identification of binding activity.
|
J Biomed Sci
|
2007
|
0.77
|
|
67
|
Immunological priming induced by a two-dose series of H5N1 influenza antigen, administered alone or in combination with two different formulations of AS03 adjuvant in adults: Results of a randomised single heterologous booster dose study at 15 months.
|
Vaccine
|
2013
|
0.76
|
|
68
|
Assessment of Prime-boost Vaccination Using an AS03B-adjuvanted Influenza A (H5N1) Vaccine: A Randomized Trial in Children of Three to Less Than Eighteen Years of Age.
|
Pediatr Infect Dis J
|
2016
|
0.76
|
|
69
|
Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine in Children 6 Months to 17 Years of Age, Previously Vaccinated with an AS03-Adjuvanted A(H1N1)Pdm09 Vaccine: Two Open-label, Randomized Trials.
|
Pediatr Infect Dis J
|
2015
|
0.76
|